Synonyms: 4-[6-Methoxy-7-[3-(1-piperidinyl)propoxy]-4-quinazolinyl]-N-[4-(1-methylethoxy)phenyl]-1-piperazinecarboxamide hydrochloride; CT 53518 hydrochloride; CT-53518 hydrochloride; CT53518 hydrochloride; MLN 518 hydrochloride; MLN-518 hydrochloride; MLN518 hydrochloride; N-(4-Isopropoxyphenyl)-4-(6-methoxy-7-(3-(piperidin-1-yl)propoxy)quinazolin-4-yl)piperazine-1-carboxamide hydrochloride
Molecular Formula: C31H42N6O4 · xHCl
Linear Structural Formula: C31H42N6O4 · xHCl
Purity: >=98% (HPLC)
Storage: 2-8C
Biochem Physiol Actions: Tandutinib (CT53518, MLN518) is a potent receptor tyrosine kinase inhibitor against PDGFRbeta, c-Kit, Flt3 (IC50 = 0.20, 0.17, 0.22, 3.43 muM, respectively, against 8 nM PDGF-BB induced autophosphorylation of betaPDGFR, betaPDGFR/c-Kit, betaPDGFR/Flt3, betaPDGFR/CSF-1R chimera expressed in CHO cells; IC50 =30 muM against KDR, EFGR, FGFR, InsR, Abl, Src, PKA, PKC, ERK2, MEK1, MKK4/6, p38). Tandutinib prolongs the survival in murine CMML (Baf3 with Tel/betaPDGFR chimera) and Flt-3/ITD AML leukemia models (60 mg/kg bid p.o.) with good oral bioavailability.